Tempest Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Financial Results | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly1.8MTarget: Sufficient capital to fund operations through mid-2027
Accumulated Deficit Quarterly270.1MTarget: Reduction through commercialization or strategic licensing
TPST-2003 Complete Response (CR) Rate in CAR-T-Naïve Patients Annually10,000.0%Target: Maintain high efficacy signal in registrational trials
Watch Items
- Nasdaq Stockholders' Equity ComplianceTrigger: Stockholders' equity below $2,500,000 (reported at $822,000 as of March 31, 2026)Action: Submit a compliance plan to Nasdaq by July 6, 2026, and execute capital-raising or warrant-exercise strategies to restore equity above the threshold.
- Board and Committee Independence GapsTrigger: Lack of a majority of independent directors and under-sized committees following recent resignationsAction: Appoint new independent directors to satisfy Nasdaq Listing Rule 5605 requirements within the designated cure period.
- Amezalpat (TPST-1120) Phase 3 InitiationTrigger: Securing a strategic partner or separate funding to operationalize the pivotal Phase 3 trial in first-line HCCAction: Advance business development discussions led by the newly appointed Head of Business Development to secure a global co-development or licensing agreement.
Research as of 20 Jun 2026